Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of 7.37 billion. The enterprise value is 18.62 billion.
| Market Cap | 7.37B |
| Enterprise Value | 18.62B |
Important Dates
The next estimated earnings date is Thursday, August 28, 2025.
| Earnings Date | Aug 28, 2025 |
| Ex-Dividend Date | Jun 18, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.35% |
| Shares Change (QoQ) | -0.66% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 7.55 and the forward PE ratio is 6.76.
| PE Ratio | 7.55 |
| Forward PE | 6.76 |
| PS Ratio | 0.09 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | 2.28 |
| P/OCF Ratio | 2.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.83, with an EV/FCF ratio of 5.77.
| EV / Earnings | 19.07 |
| EV / Sales | 0.23 |
| EV / EBITDA | 5.83 |
| EV / EBIT | 7.24 |
| EV / FCF | 5.77 |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.34 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 3.56 |
| Debt / FCF | 3.37 |
| Interest Coverage | 6.65 |
Financial Efficiency
Return on equity (ROE) is 8.24% and return on invested capital (ROIC) is 5.47%.
| Return on Equity (ROE) | 8.24% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.47% |
| Return on Capital Employed (ROCE) | 12.48% |
| Revenue Per Employee | 737,197 |
| Profits Per Employee | 9,024 |
| Employee Count | 108,217 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.80% in the last 52 weeks. The beta is 0.56, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -13.80% |
| 50-Day Moving Average | 11.69 |
| 200-Day Moving Average | 12.48 |
| Relative Strength Index (RSI) | 51.54 |
| Average Volume (20 Days) | 15,072 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of 79.78 billion and earned 976.57 million in profits. Earnings per share was 0.31.
| Revenue | 79.78B |
| Gross Profit | 6.00B |
| Operating Income | 2.43B |
| Pretax Income | 1.90B |
| Net Income | 976.57M |
| EBITDA | 2.72B |
| EBIT | 2.43B |
| Earnings Per Share (EPS) | 0.31 |
Balance Sheet
The company has 6.25 billion in cash and 10.87 billion in debt, giving a net cash position of -4.62 billion.
| Cash & Cash Equivalents | 6.25B |
| Total Debt | 10.87B |
| Net Cash | -4.62B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 17.80B |
| Book Value Per Share | 3.55 |
| Working Capital | 13.00B |
Cash Flow
In the last 12 months, operating cash flow was 3.41 billion and capital expenditures -181.85 million, giving a free cash flow of 3.23 billion.
| Operating Cash Flow | 3.41B |
| Capital Expenditures | -181.85M |
| Free Cash Flow | 3.23B |
| FCF Per Share | n/a |
Margins
Gross margin is 7.53%, with operating and profit margins of 3.04% and 1.22%.
| Gross Margin | 7.53% |
| Operating Margin | 3.04% |
| Pretax Margin | 2.39% |
| Profit Margin | 1.22% |
| EBITDA Margin | 3.41% |
| EBIT Margin | 3.04% |
| FCF Margin | 4.05% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 4.26%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 4.26% |
| Dividend Growth (YoY) | 7.35% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 29.23% |
| Buyback Yield | -0.35% |
| Shareholder Yield | 3.90% |
| Earnings Yield | 13.25% |
| FCF Yield | 43.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.12 |
| Piotroski F-Score | n/a |